| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.8M | -3.3% | +51.3% |
| R&D Expense | $94.7M | -2.4% | -23.2% |
| SG&A Expense | $30.5M | +12.2% | +0.0% |
| Operating Income | -$111.5M | -1.3% | +23.0% |
| Net Income | -$101.3M | -0.1% | +25.3% |
| EPS (Basic) | -$0.92 | +6.1% | +31.3% |
| EPS (Diluted) | -$0.92 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $193.4M | +23.8% | +60.5% |
| Short-term Investments | $317.7M | +4.7% | -40.9% |
| Accounts Receivable | $11.1M | -2.7% | +24.8% |
| Current Assets | $581.9M | +17.3% | -18.1% |
| Total Assets | $925.3M | +2.9% | -21.1% |
| Current Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$325.5M | — | — |
| Capital Expenditures | $1.0M | — | — |
| Investing Cash Flow | $200.5M | — | — |
| Financing Cash Flow | $129.5M | — | — |
| Free Cash Flow | -$326.5M | — | — |
| +6.1% |
| +31.3% |
| $93.7M |
| -1.9% |
| -11.3% |
| Total Liabilities | $176.9M | -3.7% | -16.1% |
| Stockholders' Equity | $748.4M | +4.6% | -22.3% |